◎赵彬彬 记者 杨烨 先达股份表示，今年二季度，公司主打产品烯草酮受市场供需关系影响售价显著上涨，有效带动产品毛 利率大幅提升。同时，创制产品吡唑喹草酯成功投放市场，为公司业绩增长注入新动能。 经历了近几年的低迷，农化行业在2025年初呈现局部性、结构性改善。东方财富Choice数据显示，截至 8月25日，22家披露半年报或业绩预告的农化上市公司中，18家企业业绩向好，其中先达股份等11家公 司净利润实现或预计实现超100%增长。不过，仍有红太阳等4家公司业绩出现明显下滑。 多位受访者认为，尽管农化行业扭转了单边下行态势，上市公司业绩也出现明显回升，但更多是局部 性、结构性的改善。从整体来看，国内农化行业景气度仍处于低位区间，行业全面回升仍需过剩产能进 一步出清以及创制类产品进一步增长。 11家公司净利增长超100% 尽管农化行业目前还处于周期底部，但部分具有竞争优势的龙头企业的业绩已现复苏迹象。 润丰股份近日交出了不俗的半年报成绩单。上半年，公司实现营业收入65.31亿元，同比增长14.94%； 归属于上市公司股东的净利润5.56亿元，较去年同期大增205.62%。特别是二季度，公司营业收入同比 增长28. ...

丨证券研究报告丨 公司研究丨点评报告丨扬农化工（600486.SH） [Table_Title] 行业周期底部，公司逆势增长 报告要点 [Table_Summary] 公司发布 2025 半年报，2025H1 实现收入 62.3 亿元，同比变动+9.4%，归属净利润 8.1 亿元， 同比变动+5.6%，归属扣非净利润 8.0 亿元，同比变动+7.9%。2025Q2 实现收入 29.9 亿元， 同比变动+18.6%，环比变动-7.6%，归属净利润 3.7 亿元，同比变动+11.1%，环比变动-14.7%， 归属扣非净利润 3.7 亿元，同比变动+17.5%，环比变动-15.0%。公司拟向全体股东每 10 股派 发现金红利人民币 2.40 元（含税）。 分析师及联系人 [Table_Author] 马太 王明 SAC：S0490516100002 SAC：S0490521030001 SFC：BUT911 SFC：BVA881 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 扬农化工（600486.SH） cjzqdt11111 [Table_Title2] 行业周 ...

自主登记与市场布局双轮驱动。目前，公司烯草酮、咪唑乙烟酸、异噁草松、烯酰吗啉等原药和制剂产 品，在主要目标市场的自主登记布局已全部完成，同时正在积极推动获批产品与客户的商务合作。在阿 根廷，公司成功获得2,4-滴丁酸丁酯、吡草醚制剂认证。独家产品氟吡酰草胺、2,4-滴丁酸在欧盟、澳 大利亚市场实现稳定供货，并在东南亚及中南美洲进入正式登记阶段。公司创制产品吡唑喹草酯、苯丙 草酮在美洲主要水稻主产国启动自主登记，药效反响良好，展现出巨大的商业潜力。 投资建议：公司专注高端除草剂产品开发，并形成了差异化的制剂证件优势，未来随着公司新的创制药 产品上市以及新项目陆续投产，公司业绩有望保持快速增长。考虑到公司烯草酮受市场供需关系影响售 价显著上涨，我们上调公司业绩预期，预计公司2025-2027 年归母净利润分别为2.34、2.99、3.70 亿 元，同比增速分别为+1005.31%、+27.66%、+23.75%，对应PE 分别为20X、15X、12X，维持"推荐"评 级。 稳步推进创制化合物的全产业链研发与产业化。公司专注于高端除草剂领域的科技创新和产品开发，截 至目前，公司拥有58 项发明专利，首款创制除草剂产 ...

辽宁优创开启新一轮成长。葫芦岛一期包括年产4500吨杀虫剂、8050吨除草剂和3100吨杀菌剂、7000吨 农药中间体。据公司2024年年报，辽宁优创一期投资预算数34.8亿元，累计投入已达80%，其中，一阶 段已经建成，正在陆续进行调试生产，功夫菊酯、烯草酮等多个品种已拿出合格产品，二阶段正在设备 安装阶段。此外，公司正在加快编制葫芦岛二期项目清单。 自主研发+先正达赋能，打造领先农药创制平台公司自主创制水平领先，形成"农研公司+扬农化工本 部"的创制平台。据2024年年报，在我国年销售额超过亿元的6个自主创制品种中，公司有3个。 本篇报告解决了以下核心问题：1、跟踪下游制剂库存数据、粮食作物价格，判断农药需求复苏，周期 见底回升；2、详细梳理扬农各工厂主要产品供需情况，行业扩张进入尾声，一体化配套的低成本优势 使公司具有超越同行的底部利润。 终端去库叠加粮价企稳，农药需求回暖，原药价格见底2021-2022年行业超额采购，制剂巨头先正达、 安道麦库存金额在2022下半年达到最高点，富美实的库存金额则在2023Q2达到峰值，库存/营业收入的 比例则普遍在2023Q3达到最高点。2024年底，三家农化企业库存 ...

截至目前，已有超过千家A股上市公司披露了2025年半年报。数据显示，多个赛道的龙头企业2025年上半年业绩实现 稳健增长。 A股半年报披露已超1000家 A股上市公司2025年半年报正如火如荼披露中，截至发稿，已披露2025年半年报的A股上市公司数量合计超过了1000家。 数据显示，在已披露半年报的逾千家上市公司中，逾600家公司2025年上半年归属于上市公司股东的净利润同比正增长， 超过百家公司归属于上市公司股东的净利润同比翻倍；值得一提的是，先达股份、智明达、容知日新等多家公司归属于 上市公司股东的净利润同比增长超过10倍。 如先达股份日前披露的2025年半年报显示，公司2025年上半年实现营业总收入14.23亿元，较上年同期增长11.82%，归属 于上市公司股东的净利润1.36亿元，较上年同期暴增2561.58%。公司表示，第二季度，公司主打产品烯草酮受市场供需 关系影响售价显著上涨，有效带动产品毛利率大幅提升。同时，创制产品吡唑喹草酯成功投放市场，为公司业绩增长注 入新动能。在多因素共同作用下，公司经营业绩实现大幅改善。 智明达披露的2025年半年报显示，公司2025年上半年实现营业总收入2.95亿元 ...

截至目前，已有超过千家A股上市公司披露了2025年半年报。数据显示，多个赛道的龙头企业2025年上半年业绩实现稳健增长。 A股半年报披露已超1000家 A股上市公司2025年半年报正如火如荼披露中，截至发稿，已披露2025年半年报的A股上市公司数量合计超过了1000家。 数据显示，在已披露半年报的逾千家上市公司中，逾600家公司2025年上半年归属于上市公司股东的净利润同比正增长，超过百家公司归属于上市公司股东的净利 润同比翻倍；值得一提的是，先达股份、智明达、容知日新等多家公司归属于上市公司股东的净利润同比增长超过10倍。 如先达股份日前披露的2025年半年报显示，公司2025年上半年实现营业总收入14.23亿元，较上年同期增长11.82%，归属于上市公司股东的净利润1.36亿元，较上 年同期暴增2561.58%。公司表示，第二季度，公司主打产品烯草酮受市场供需关系影响售价显著上涨，有效带动产品毛利率大幅提升。同时，创制产品吡唑喹草 酯成功投放市场，为公司业绩增长注入新动能。在多因素共同作用下，公司经营业绩实现大幅改善。 智明达披露的2025年半年报显示，公司2025年上半年实现营业总收入2.95亿元，较上 ...

Core Insights - As of August 20, 2025, 623 private listed companies in A-shares have disclosed their semi-annual performance, with 528 achieving profitability, representing over 80% [1][2] - Among the profitable companies, 318 reported year-on-year net profit growth, with 46 successfully turning losses into profits [1][2] - The strong performance is attributed to companies seizing opportunities in sectors such as commercial aviation, robotics, and AI computing power, alongside increased R&D investments [1] Group 1: Performance Overview - 318 companies achieved positive net profit growth, with 59 of them reporting growth exceeding 100% [3] - Notably, 17 companies with a market capitalization of less than 5 billion yuan experienced profit growth exceeding 2000% [3] - Leading companies like CATL, Industrial Fulian, WuXi AppTec, and Great Wall Motors reported net profits exceeding 5 billion yuan [2] Group 2: R&D Investment and Innovation - 125 of the 318 companies had R&D expenditures accounting for more than 5% of their revenue, indicating a strong focus on innovation [5] - Companies like Guangli Microelectronics reported a staggering 518.42% increase in net profit, supported by a high R&D expenditure ratio of 58.57% [5] - The emphasis on R&D and innovation is seen as a critical driver for long-term growth, with many companies capitalizing on emerging industries and market opportunities [5] Group 3: Sector Performance - The electronics, basic chemicals, and machinery equipment sectors led the profitability rankings, with 67, 66, and 62 companies respectively achieving profits [2] - AIoT market continued to grow, with companies like Rockchip reporting a 191.61% increase in net profit, driven by expansion in automotive electronics and industrial applications [6] - Companies such as Weicai Technology benefited from trends in smart driving and AI computing, achieving a net profit increase of 831.03% [5]

Group 1: Company Performance - As of August 20, 845 A-share listed companies have released their semi-annual reports, with 130 companies reporting a net profit attributable to shareholders that increased by over 100% year-on-year [1] - Factors driving high growth in these companies include improved market supply and demand for main products and the extension of the industrial chain [1] - For instance, Shandong Xianda Agricultural Chemical Co., Ltd. reported significant profit growth due to a rise in the price of its main product, acetochlor, and the successful market launch of a new product, pyrazolyl quinoline [1] Group 2: Industry Trends - Several poultry farming companies have also shown impressive performance in the first half of the year, attributed to lower feed costs and increased profit margins [1] - Analysts indicate that leading companies are focusing on high-value-added product channels, enhancing their market position through full industry chain development [1] Group 3: Dividend Policies - Many listed companies are implementing substantial dividend plans to share development dividends with investors, reflecting a consensus on returning profits [2] - Cash dividends are seen as a positive signal for the health of the capital market, indicating real profitability and cash flow stability [2] - A consistent dividend policy can attract long-term capital, optimize investor structure, and enhance market resilience [2] Group 4: Market Implications - The trend of active dividend distribution among Chinese listed companies aligns with international market practices, aiding in the transition from speculation to value-driven investment [3] - This phenomenon is indicative of improved company quality and a sign of ongoing optimization in the capital market ecosystem [3] - Companies with strong performance and proactive investor returns are expected to gain more favor in the capital market as more semi-annual reports are released [3]

Market Strategy - The market experienced a pullback after a rise, with the liquor sector rebounding [7] - The overall A-share market saw a slight decline, with the Shanghai Composite Index down 0.02% and the ChiNext Index down 0.17% [7][8] - Small and micro-cap stocks outperformed larger stocks, with the North Star 50 Index increasing by 1.27% [7] Economic Insights - From January to July, the national general public budget revenue grew by 0.1% year-on-year, with tax revenue declining by 0.3% [14][15] - The People's Bank of China conducted a 7-day reverse repurchase operation of 580.3 billion yuan, indicating a net injection of 465.7 billion yuan into the market [18][19] Industry Dynamics - The National Radio and Television Administration encourages the broadcasting of micro-short dramas and the introduction of excellent foreign programs [25] - In July 2025, China's gaming market revenue grew by 4.62% year-on-year, with self-developed games' overseas revenue increasing by 6.76% [27][28] Company Tracking - For Hebang Bio (603077.SH), the methionine business saw explosive growth, with the company achieving a revenue of 3.921 billion yuan in the first half of 2025 [29][30] - Xinda Co., Ltd. (603086.SH) reported a revenue of 1.423 billion yuan, a year-on-year increase of 11.82%, driven by a recovery in the pesticide market [32][33]

Core Viewpoint - The company has demonstrated significant growth in revenue and net profit in the first half of 2025, driven by product optimization and market demand for its innovative agricultural solutions [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.423 billion yuan, representing a year-on-year increase of 11.82% [1]. - The net profit attributable to shareholders reached 136 million yuan, marking a substantial year-on-year growth of 2561.58% [1]. - The adjusted net profit after excluding non-recurring items was 131 million yuan, compared to a loss of 82,370 yuan in the same period last year [1]. Group 2: Product Development and Market Strategy - The company focuses on the research, production, and sales of environmentally friendly agricultural chemicals, with key products including herbicides and fungicides [2]. - The main product, Acetochlor, saw a significant price increase due to market supply and demand dynamics, leading to a substantial rise in gross profit margin [2]. - The newly launched product, Pyrazosulfuron-ethyl, has quickly gained market recognition as a herbicide for rice fields, contributing to the company's growth [2]. - The company is enhancing its competitive edge by optimizing traditional products and developing differentiated solutions for the wheat field herbicide market [2][3]. Group 3: Market Trends and Opportunities - The domestic agricultural chemical industry is showing signs of stabilization, with improvements in supply and demand dynamics [6]. - The price indices for herbicides, insecticides, and fungicides have shown moderate recovery, alleviating previous market imbalances [6]. - In the overseas market, the demand for agricultural chemicals is recovering, with significant year-on-year growth in export values for insecticides, fungicides, and herbicides [6]. - The company plans to leverage its innovative capabilities to enhance existing products and create a comprehensive industry layout to improve market competitiveness [6]. Group 4: Research and Development - The company has a robust pipeline of research projects, focusing on various crops and biotechnologies, aiming to commercialize a new compound every two years [7].